Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Arch. endocrinol. metab. (Online) ; 61(1): 81-89, Jan.-Feb. 2017. tab
Artículo en Inglés | LILACS | ID: biblio-838415

RESUMEN

ABSTRACT Radioiodine (RAI)-refractory thyroid cancer is an uncommon entity, occurring with an estimated incidence of 4-5 cases/year/million people. RAI refractoriness is more frequent in older patients, in those with large metastases, in poorly differentiated thyroid cancer, and in those tumors with high 18-fluordeoxyglucose uptake on PET/CT. These patients have a 10-year survival rate of less than 10%. In recent years, new therapeutic agents with molecular targets have become available, with multikinase inhibitors (MKIs) being the most investigated drugs. Two of these compounds, sorafenib and lenvatinib, have shown significant objective response rates and have significantly improved the progression-free survival in the two largest published prospective trials on MKI use. However, no overall survival benefit has been achieved yet. This is probably related to the crossover that occurs in most patients who progress on placebo treatment to the open treatment of these studies. In consequence, the challenge is to correctly identify which patients will benefit from these treatments. It is also crucial to understand the appropriate timing to initiate MKI treatment and when to stop it. The purpose of this article is to define RAI refractoriness, to summarize which therapies are available for this condition, and to review how to select patients who are suitable for them.


Asunto(s)
Humanos , Neoplasias de la Tiroides/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/uso terapéutico , Radioisótopos de Yodo/uso terapéutico , Antineoplásicos/uso terapéutico , Tolerancia a Radiación , Neoplasias de la Tiroides/mortalidad , Neoplasias de la Tiroides/radioterapia , Insuficiencia del Tratamiento , Retratamiento , Manejo de la Enfermedad
2.
Korean Journal of Endocrine Surgery ; : 1-7, 2013.
Artículo en Coreano | WPRIM | ID: wpr-152202

RESUMEN

Most patients with thyroid cancer (of follicular cell origin) are successfully managed with a combination of surgery, radioactive iodine (131I-RAI), and suppression of thyroid-stimulating hormone with thyroid hormone replacement, obtaining survival rates approaching 90% at 20 years. Although the prognosis of patients with differentiated thyroid carcinoma (DTC) is favorable, recurrence occurs in up to 30% patients. In addition, many patients with recurrent or metastatic disease, as well as those with less differentiated tumors, will have a much poorer prognosis and lose their ability to concentrate functional iodine and are therefore not targeted by 131I-RAI therapy. There are many treatment options but no definitive treatment for radioiodine refractory thyroid cancer. This paper will discuss the roles of surgical treatment for patients with radioiodine refractory thyroid cancer.


Asunto(s)
Humanos , Yodo , Métodos , Pronóstico , Recurrencia , Tasa de Supervivencia , Glándula Tiroides , Neoplasias de la Tiroides , Tirotropina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA